Renal cell carcinoma (RCC) incidence is rising globally, with significant mortality especially in advanced stages. Screening programs, particularly using focused renal ultrasound, show promise for early detection in high-risk populations but face challenges including overdiagnosis and cost-effectiveness uncertainties.
Background
RCC accounts for over 430,000 new cases and 175,000 deaths annually worldwide. Established risk factors include older age, male sex, smoking, hypertension, and obesity. Early-stage RCC detection dramatically improves survival rates compared to metastatic disease. Given the high mortality and asymptomatic nature of early RCC, screening initiatives aim to improve outcomes by detecting tumors at a treatable stage.
Data Highlights
In 2020, RCC incidence exceeded 430,000 cases with over 175,000 deaths globally. Stage I RCC patients have 1-year and 5-year survival rates of 96% and 86%, respectively, versus 39% and 12% for metastatic cases. Focused renal ultrasound has demonstrated cost-effectiveness and potential survival benefits in early detection. However, no liquid biomarkers or novel imaging modalities have yet been validated for routine screening use.
Key Findings
RCC incidence is increasing due to rising prevalence of risk factors and incidental detection.
Early-stage RCC diagnosis significantly improves survival compared to metastatic disease.
Focused renal ultrasound is a cost-effective screening tool with potential survival benefits.
Emerging liquid biomarkers and innovative imaging techniques lack validation for clinical implementation.
Screening high-risk populations may improve RCC care but requires further evidence on cost-effectiveness and harms.
Potential harms of screening include overdiagnosis, psychological distress, and financial toxicity.
Clinical Implications
Clinicians should consider RCC screening primarily in high-risk individuals using focused renal ultrasound, balancing benefits of early detection against risks of overdiagnosis. Current evidence does not support routine use of liquid biomarkers or novel imaging for screening. Further research is needed to define optimal screening protocols and target populations to maximize clinical benefit and cost-effectiveness.
Conclusion
RCC screening holds promise to improve early detection and survival in high-risk populations, but uncertainties remain regarding optimal strategies and potential harms. Focused renal ultrasound currently represents the most viable screening modality pending further validation of emerging tools.
References
EAU Young Academic Urologists' Working Group on Renal Cancer, 2021 -- A Comprehensive Review of Renal Cell Carcinoma Screening Initiatives
Colorectal cancer (CRC) impacts about 1 in 13,000 pregnancies in the United States. This article follows the case of a 36-year-old woman diagnosed with CRC while pregnant and highlights considerations around CRC diagnosis and cancer treatment during pregnancy.
